Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Short term Debt: 2009-2024

Historic Short term Debt for Fresenius Medical Care AG (FMS) over the last 17 years, with Sep 2025 value amounting to $2.4 billion.

  • Fresenius Medical Care AG's Short term Debt rose 37.73% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 37.73%. This contributed to the annual value of $1.9 billion for FY2024, which is 5.38% up from last year.
  • Per Fresenius Medical Care AG's latest filing, its Short term Debt stood at $2.4 billion for Q3 2025, which was up 16.32% from $2.1 billion recorded in Q2 2025.
  • Over the past 5 years, Fresenius Medical Care AG's Short term Debt peaked at $2.4 billion during Q3 2025, and registered a low of $59.0 million during Q3 2022.
  • Its 3-year average for Short term Debt is $1.6 billion, with a median of $1.8 billion in 2023.
  • As far as peak fluctuations go, Fresenius Medical Care AG's Short term Debt plummeted by 93.04% in 2022, and later surged by 1,205.53% in 2023.
  • Fresenius Medical Care AG's Short term Debt (MRQ) stood at $764.1 million in 2021, then soared by 138.55% to $1.8 billion in 2022, then dropped by 1.10% to $1.8 billion in 2023, then increased by 5.95% to $1.9 billion in 2024, then increased by 26.29% to $2.4 billion in 2025.
  • Its Short term Debt was $2.4 billion in Q3 2025, compared to $2.1 billion in Q2 2025 and $1.8 billion in Q1 2025.